How to Get Zetia (Ezetimibe) in South Dakota

What Is Ezetimibe and Why Do South Dakota Patients Use It?

Ezetimibe is an oral cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol uptake by roughly 54% [1]. South Dakota's adult population carries a cardiovascular disease burden consistent with national rates: the CDC reports that 11.7% of U.S. adults have been diagnosed with coronary heart disease [2], a condition for which LDL lowering is a primary intervention.

The drug is FDA-approved as an adjunct to diet for primary hyperlipidemia (as monotherapy or with a statin), mixed hyperlipidemia (with fenofibrate), and homozygous familial hypercholesterolemia (with atorvastatin or simvastatin) [3]. The prescribing label also covers sitosterolemia and homozygous familial sitosterolemia [3].

Ezetimibe monotherapy lowers LDL-C by 18 to 23% [4]. When added to ongoing statin therapy, it produces an additional 21 to 24% LDL-C reduction beyond the statin alone [5]. The American College of Cardiology/American Heart Association 2018 cholesterol guideline states: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe is reasonable" [6]. That language reflects a Class IIa recommendation, meaning good evidence supports the practice.

The landmark IMPROVE-IT trial (N=18,144) randomized high-risk post-acute coronary syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo [7]. At a median 6-year follow-up, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm, translating to a 6.4% relative reduction in the primary composite cardiovascular endpoint (P<0.001) [7]. That trial provided the first prospective proof that non-statin LDL lowering with ezetimibe reduces hard cardiovascular events on top of statin therapy [7].

Who Can Prescribe Zetia in South Dakota?

Any of four provider types can legally prescribe ezetimibe to a South Dakota patient.

Medical Doctors (MD) and Doctors of Osteopathic Medicine (DO) hold full prescriptive authority in SD under SDCL 36-4 [8]. Primary care physicians, cardiologists, and endocrinologists routinely manage dyslipidemia and are the most common prescribers.

Nurse Practitioners (NPs) in South Dakota practice under full independent authority after completing 2,080 supervised hours, as established by SD Senate Bill 110 (2015) [9]. An NP does not need a supervising physician to prescribe ezetimibe. Telehealth NPs licensed in SD can initiate, adjust, or refill ezetimibe prescriptions for SD-resident patients.

Physician Assistants (PAs) practice under a collaborative agreement with a supervising physician per SDCL 36-4A [10]. A PA can prescribe ezetimibe within that agreement's scope.

Telehealth providers licensed in South Dakota satisfy the state's valid prescribing relationship requirement when they perform a synchronous audio-video encounter or, in some cases, an asynchronous encounter if the platform documents clinical decision-making. South Dakota's telehealth parity law (SDCL 58-17-114) requires most insurance plans to cover telehealth visits at the same rate as in-person visits [11].

What Labs Are Needed Before Getting a Zetia Prescription in South Dakota?

A fasting lipid panel is the minimum required before any clinician writes an ezetimibe prescription. The panel includes total cholesterol, LDL-C, HDL-C, and triglycerides, and should be drawn after a 9 to 12 hour fast to minimize triglyceride interference with calculated LDL-C [12].

Most South Dakota clinicians also order a comprehensive metabolic panel (CMP) to capture baseline liver enzymes (ALT, AST). Ezetimibe alone has not shown clinically significant hepatotoxicity in trials, but the ACC/AHA guideline recommends baseline liver function testing before initiating lipid-lowering combination therapy [6]. If a statin is co-prescribed, creatine kinase (CK) measurement may be added to establish a myopathy baseline [6].

Patients with suspected familial hypercholesterolemia should have a genetic lipid panel or LDL-C measured in first-degree relatives to meet FH diagnostic criteria per the Dutch Lipid Clinic Network score [13]. South Dakota has no state-run FH registry, so documentation falls to the treating clinician.

Labs drawn at any CLIA-certified SD facility, including Sanford Health, Monument Health, or regional critical-access hospitals, satisfy this requirement. Direct-to-consumer labs such as Quest and LabCorp also serve SD residents and can transmit results electronically to a telehealth provider, cutting the time from order to prescription by 24 to 48 hours compared with waiting for a mailed report [14].

How to Get a Zetia Prescription Through Telehealth in South Dakota

Telehealth prescribing of ezetimibe in South Dakota is legal and available today. The process follows four steps.

Step 1: Choose a licensed provider. Confirm the platform's prescribers hold active SD licensure. The South Dakota Board of Medical and Osteopathic Examiners publishes a public license-verification tool at sdsos.gov/. Any provider listed as "current and active" can legally prescribe [15].

Step 2: Upload or order labs. Most telehealth platforms accept results from the past 12 months. If results are older, or if this is a first-time lipid evaluation, schedule a lab draw before the video visit. Results typically return within 24 hours at national lab chains.

Step 3: Complete the synchronous video visit. The clinician will review your lipid values, cardiovascular risk factors (age, sex, smoking status, blood pressure, diabetes status), current medications, and any contraindications. The visit takes 15 to 25 minutes on average [16]. The provider calculates your 10-year ASCVD risk using the Pooled Cohort Equations, a tool endorsed by the AHA/ACC guideline [6].

Step 4: Receive the prescription. The provider sends the prescription electronically to your preferred SD pharmacy or to a mail-order pharmacy licensed to ship to South Dakota. Ezetimibe is not a controlled substance, so e-prescribing follows no additional federal restriction beyond DEA regulations for non-controlled drugs [17].

The four-step framework above reflects HealthRX's internal care pathway for lipid-lowering telehealth visits, designed to align with ACC/AHA 2018 guideline decision points and South Dakota prescribing statutes.

South Dakota Pharmacies Carrying Ezetimibe

Every major pharmacy chain with SD locations stocks generic ezetimibe 10 mg tablets. Sanford Health system pharmacies, Walgreens, CVS, Walmart Pharmacy, Lewis Drug (a SD-based regional chain with 24 locations), and most independent community pharmacies in Sioux Falls, Rapid City, Aberdeen, and Watertown carry the generic [18].

Cash price: Without insurance, generic ezetimibe 10 mg (30 tablets) runs approximately $13, $22 at GoodRx rates at South Dakota pharmacies, compared with $200, $280 for brand-name Zetia at the same quantity [19]. GoodRx and manufacturer copay cards can reduce brand-name cost for commercially insured patients.

Mail-order pharmacies: SD-licensed mail-order pharmacies, or out-of-state pharmacies licensed by the South Dakota Board of Pharmacy, can legally ship ezetimibe to SD addresses [20]. A 90-day supply via mail order typically costs less than three one-month fills at retail. Most major pharmacy benefit managers (CVS Caremark, ExpressScripts, OptumRx) include ezetimibe on their national formularies.

503A compounding pharmacies: State-licensed 503A compounding pharmacies in South Dakota can compound ezetimibe in non-commercially available forms (for example, custom oral suspensions for patients who cannot swallow tablets), but they cannot manufacture copies of the commercially available 10 mg tablet [21]. SD Board of Pharmacy rules require 503A pharmacies to compound only on receipt of a valid, patient-specific prescription [20].

Prior Authorization Requirements in South Dakota

Prior authorization (PA) is the main access barrier for ezetimibe in South Dakota. Most commercial plans in the state require documentation of a statin trial before approving ezetimibe, and South Dakota Medicaid does not currently cover ezetimibe for the standard hyperlipidemia adjunct indication.

A typical PA submission for a South Dakota commercial plan must include: a current fasting lipid panel (dated within 90 days), documentation of at least 12 weeks of maximally tolerated statin therapy, the calculated 10-year ASCVD risk score, and the prescribing provider's clinical rationale if statin intolerance is claimed [6].

The ACC/AHA guideline defines statin intolerance as "inability to tolerate at least 2 statins (one at the lowest available daily dose)" [6]. Getting that definition into the PA letter, with supporting visit notes documenting myalgia or hepatotoxicity, is the most common path to approval for patients who cannot take statins.

If initial PA is denied, South Dakota law under SDCL 58-17-167 requires insurers to provide a written denial with the specific clinical criteria that were not met, and grants patients a right to an expedited external appeal within 72 hours when the treating clinician certifies medical urgency [22]. Appeals that include a physician-authored letter citing the IMPROVE-IT cardiovascular outcome data and the ACC/AHA Class IIa recommendation have a higher approval rate than submissions without guideline citation [23].

South Dakota Medicaid recipients who do not qualify for ezetimibe coverage may access it via the Organon Zetia patient assistance program or generic manufacturer patient assistance programs, which do not require state Medicaid approval.

What to Expect After Starting Ezetimibe in South Dakota

LDL-C begins to fall within two weeks of the first dose. The maximum effect on fasting lipids is typically visible at the four-week mark, which is when most clinicians schedule a repeat fasting lipid panel [4].

Ezetimibe 10 mg is taken once daily, with or without food, at any time of day. No dose adjustment is required for renal impairment. Mild hepatic impairment does not require a dose change, but the manufacturer and FDA label advise against use in patients with moderate or severe hepatic impairment because of altered drug metabolism [3].

The most common adverse effects reported in clinical trials were upper respiratory infections (13.0% versus 11.1% placebo), diarrhea (4.1% versus 3.7% placebo), and arthralgia (3.0% versus 2.2% placebo) [3]. Myopathy is rare with ezetimibe alone but becomes a consideration when the drug is added to high-dose statins; the prescribing label specifically notes increased myopathy risk when combined with simvastatin 80 mg [3].

A follow-up lipid panel at four weeks confirms response. If LDL-C remains above target, the clinician may add or intensify statin therapy, or discuss a PCSK9 inhibitor (evolocumab or alirocumab) for very high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe [6]. The ACC/AHA guideline sets that 70 mg/dL threshold for secondary prevention patients with very high-risk features [6].

Regular monitoring in stable patients is typically a lipid panel every 3 to 12 months depending on cardiovascular risk category and whether treatment targets have been met [6].

Transferring an Existing Zetia Prescription to South Dakota

Patients relocating to South Dakota can transfer a non-controlled prescription for ezetimibe from any out-of-state pharmacy to an SD-licensed pharmacy. Federal law and South Dakota Board of Pharmacy rules allow a one-time transfer of remaining refills between pharmacies [24]. Electronic transfers between chain pharmacies (for example, CVS to CVS, Walgreens to Walgreens) are instantaneous. Independent pharmacy-to-independent pharmacy transfers require a phone call between pharmacists.

If the original prescription has no remaining refills, the out-of-state prescriber can call or e-prescribe a new supply to an SD pharmacy. Alternatively, establishing care with a new SD-licensed provider (including via telehealth) and having that provider issue a new prescription is the cleanest path for patients with no active refills [17].

Patients transferring from a state where a compounded ezetimibe suspension was prescribed should note that the SD 503A pharmacy receiving the transfer must generate a new patient-specific prescription from an SD-licensed prescriber; they cannot simply accept the compounding formula from another state's pharmacy [21].

Cost and Insurance Coverage in South Dakota

Medicaid: South Dakota Medicaid (Healthy and Well Kids in SD covers pediatric enrollees; adults fall under the standard Medicaid fee-for-service program) does not currently list ezetimibe on its preferred drug list for the hyperlipidemia adjunct indication [25]. This makes generic ezetimibe a cash-pay drug for most adult Medicaid enrollees, where the out-of-pocket cost at approximately $13, $22 per month is modest.

Medicare Part D: Ezetimibe appears on most Part D plan formularies in South Dakota, commonly at Tier 2 (preferred generic) or Tier 3 (non-preferred drug) depending on the plan. The CMS 2024 Part D data show that ezetimibe is one of the 200 most-dispensed drugs under Medicare [26]. Patients in the catastrophic coverage phase pay no more than $3.40 (generics) or $8.50 (brands) per prescription under the Inflation Reduction Act changes effective 2024 [27].

Commercial insurance: Coverage varies. Most large South Dakota employers using national PBMs cover generic ezetimibe at a $10, $25 copay after a statin trial is documented. The PA process described above applies primarily to the brand-name Zetia and sometimes to generic ezetimibe under step-therapy protocols.

Manufacturer assistance: Organon's Zetia Savings Card reduces brand-name cost for eligible commercially insured patients. Income-based patient assistance through NeedyMeds and RxAssist lists several generic manufacturers offering $0 or low-cost programs for uninsured SD residents [28].